Search

Your search keyword '"Sophie Megnien"' showing total 2 results
Start Over Author "Sophie Megnien" Search Limiters Available in Library Collection
2 results on '"Sophie Megnien"'

1. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

Author

Miriam B. Vos, Lara Dimick-Santos, Ruby Mehta, Stephanie O. Omokaro, Johannes Taminiau, Elmer Schabel, David E. Kleiner, Peter Szitanyi, Piotr Socha, Jeffrey B. Schwimmer, Stephanie Noviello, Debra G. Silberg, Richard Torstenson, Veronica Miller, Joel E. Lavine, Nathalie Adda, William Baldyga, Rajarshi Banerjee, Cynthia Behling, Sherif Boulos, Gary Burgess, Dania Calboli, Edgar Charles, Rose Christian, Claude Cohen-Bacrie, Doina Cosma-Roman, Claus-Peter Danzer, Ingrid Delaet, Mark Delegge, Nicholas DiProspero, Kathleen Donohue, Laurent Fischer, Emer Fitzpatrick, Michael Fried, David Hagerty, Paula Hale, Keri Hildick, Dean Hum, Khurram Jamil, Lijuan Jiang, Saul Karpen, Matt Kelly, Rohit Kohli, Kattayoun Kordy, Nancy Krieger, Joel Lavine, Lois Lee, Eric Lefebvre, Patricia Lopez, Erica Lyons, Laura Malahias, Sophie Megnien, Peter Mesenbrink, Pansy Minnick, Christine Murray, Tien Nghiem, Nikki Nicholson, Wenjie Pang, Lisa Percival, Dan Peres, Margaret Powell, Dragos Roman, Mark Root, Claire Sampson, Arun Sanyal, Kathleen Schwarz, Star Seyedkazemi, David Shapiro, Reshma Shringarpure, Debra Silberg, Edward Smith, Robert Squires, William Treem, Pamela Vig, Miriam Vos, Mason Yamashita, Michael Zemel, and Liver Forum Pediat Working Grp

Subjects
medicine.medical_specialty, MEDLINE, Gastroenterology, Severity of Illness Index, Article, Drug Development, Non-alcoholic Fatty Liver Disease, Internal medicine, Nonalcoholic fatty liver disease, Severity of illness, medicine, Prevalence, Humans, Child, Clinical Trials as Topic, Hepatology, business.industry, Patient Selection, Age Factors, medicine.disease, Drug development, Liver, Human medicine, business, Liver pathology
Published
2019

2. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum

Author

Yuval A. Patel, Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David DeBrota, Lara Dimick-Santos, Claudia Filozof, Ruby Mehta, Arun J. Sanyal, Elmer Schabel, Brent A. Neuschwander-Tetri, Veronica Miller, Sander Bangma, Melanie Baxter, Sherif Boulos, Gary Burgess, Manu Chakravarthy, Rose Christian, Anthony Coombs, Goran Gannedahl, Richard Herrmann, Dean Hum, Joanne Imperial, Stuart Kendrick, Leigh MacConell, Sophie Megnien, Andrew Muir, Yuval Patel, Dan Peres, Stephen Rossi, Arun Sanyal, David Shapiro, Tim St Pierre, and Michael Zemel

Subjects
0301 basic medicine, Polypharmacy, medicine.medical_specialty, Pathology, Hepatology, medicine.diagnostic_test, business.industry, Gastroenterology, Disease, medicine.disease, Chronic liver disease, Comorbidity, digestive system diseases, Article, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Drug development, Nonalcoholic fatty liver disease, medicine, 030211 gastroenterology & hepatology, Intensive care medicine, business, Liver function tests
Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic liver disease worldwide and is an increasing cause of liver-related morbidity and mortality. Nonalcoholic steatohepatitis (NASH), the progressive histological subtype of the disease, is a growing target for drug design and development. Currently, no effective drug therapies exist for the management of NASH and multiple challenges exist for NASH-related clinical trials, stressing the need for a focused deliberative approach to facilitate drug development. One such challenge includes the inconsistent measurement of baseline parameters across clinical trials, which makes interpretation and comparison of trial data difficult and impedes drug development effort.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results